Phytopharm shares dive after disappointing Parkinson's drug study results

Shares in development stage pharmaceutical group Phytopharm fell sharply on Monday after the company reported that a drug it has been developing to treat Parkinson's disease did not produce any improvements in patients' symptoms during a study.

Shares in development stage pharmaceutical group Phytopharm fell sharply on Monday after the company reported that a drug it has been developing to treat Parkinson's disease did not produce any improvements in patients' symptoms during a study.

The company, which has been developing a treatment trademarked 'Cogane', published the results of a study of the drug on unmedicated patients with early stage Parkinson's disease.

Analysis of the headline results indicated that Cogane had "no beneficial effects on patients' symptoms measured by the primary or secondary endpoints in the study", Phtopharm reported.

More than 400 subjects with early-stage Parkinson's disease were randomly allocated to receive Cogane or a placebo which was taken orally once a day for up to 28 weeks.

Three different dosages of Cogane were trialled on patients and measurements were taken during the study to determine the efficacy, safety and tolerability of each dose of Cogane.

The company reported: "No statistically significant effects or trends towards improvement were seen in any of these endpoints. Analysis of the results indicates that the study was well conducted and gave a clear, albeit negative result."

Professor C Warren Olanow, Professor of Neurology and Neuroscience at Mount Sinai Medical School and Co-chief Investigator for the study commented: "This is disappointing news for the Parkinson disease community. Trophic factors that enhance and restore function to remaining nerve cells is an extremely promising approach for the treatment of neurodegenerative disorders such as Parkinson's disease.

Cogane offered the potential of providing trophic effects throughout the brain with an oral medication that was relatively safe and well tolerated. The company is to be congratulated for carrying out this important study in such a high-quality manner. Sadly, the results are negative. Nonetheless, the search for more effective therapies for the millions of patients who suffer from Parkinson's disease must continue."

Tim Sharpington, Chief Executive Officer of Phytopharm, added: "We are naturally disappointed with the outcome of this study of Cogane in patients with Parkinson's disease. Cogane had demonstrated encouraging efficacy in a wide range of industry standard pre-clinical models but this promise has not translated into clinically meaningful efficacy in this study.

"I would like to thank the investigators who conducted the trial, our collaborators and especially the patients who participated in the study, along with the Parkinson's disease community and all our stakeholders who have supported the development of Cogane.

Over the coming weeks, he said that the company would further analyse the results with its scientific advisors to better understand whether to continue the development of Cogane and Myogane.

Phytopharm's share price was down 80.5% to 1.95p at 10:52 on Monday.

Recommended

Share tips of the week – 24 September
Share tips

Share tips of the week – 24 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
24 Sep 2021
Three strong Asian stocks trading at bargain prices
Share tips

Three strong Asian stocks trading at bargain prices

Professional investor Nitin Bajaj of the Fidelity Asian Values investment trust picks three stocks that dominate their industries, earn good returns o…
20 Sep 2021
Why it pays to face up to your investment mistakes
Investment strategy

Why it pays to face up to your investment mistakes

Buying stocks can be a complicated business. But selling stocks can be tricky, too – even if you sell for the right reasons. Max King explains how to …
17 Sep 2021
Share tips of the week – 17 September
Share tips

Share tips of the week – 17 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
17 Sep 2021

Most Popular

Should investors be worried about stagflation?
US Economy

Should investors be worried about stagflation?

The latest US employment data has raised the ugly spectre of “stagflation” – weak growth and high inflation. John Stepek looks at what’s going on and …
6 Sep 2021
Two shipping funds to buy for steady income
Investment trusts

Two shipping funds to buy for steady income

Returns from owning ships are volatile, but these two investment trusts are trying to make the sector less risky.
7 Sep 2021
The times may be changing, but don’t change how you invest
Small cap stocks

The times may be changing, but don’t change how you invest

We are living in strange times. But the basics of investing remain the same: buy fairly-priced stocks that can provide an income. And there are few be…
13 Sep 2021